Initiation of new glucose-lowering therapies may act to reduce physical activity levels: pooled analysis from three randomized trials
OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown.
RESEARCH DESIGN AND METHODS. We pooled data (n = 148) from three randomised trials to investigate the effect of empagliflozin (SGLT2i) and liraglutide (GLP-1RA), in comparison to sitagliptin (dipeptidyl peptidase 4 inhibitor) and dietary therapies on accelerometer-assessed physical activity.
RESULTS: Liraglutide (-1144 steps/day; 95% CI -2069, -220), empagliflozin (-1132 steps/day; -1739, -524) and sitagliptin (-852 steps/day; -1625, -78) resulted in reduced total daily physical activity after 6 months (p< 0.01 vs. control). Moderate-to-vigorous intensity physical activity was also reduced. Dietary interventions led to no change or an increase in physical activity.
CONCLUSIONS: The initiation of all glucose lowering therapies was associated with reduced physical activity, warranting further investigation.
The SEESAW trial was funded by an investigator-initiated grant from BoehringerIngelheim. The LYDIA trial was funded by an investigator-initiated grant from Novo Nordisk. The DIASTOLIC trial was funded by a grant from the National Institute for Health Research (CDF 2014-07-045)
National Institute for Health Research (NIHR) Leicester Biomedical Research Centre
- Sport, Exercise and Health Sciences
Published inDiabetes Care
PublisherAmerican Diabetes Association
- AM (Accepted Manuscript)
Rights holder© American Diabetes Association
Publisher statementThis manuscript was accepted for publication in Diabetes Care on 26/07/2022. The final version of the paper is available on the Diabetes Care website at https://doi.org/10.2337/dc22-0888.